Pharmacogenomics

3,213 views
3,050 views

Published on

0 Comments
6 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
3,213
On SlideShare
0
From Embeds
0
Number of Embeds
8
Actions
Shares
0
Downloads
313
Comments
0
Likes
6
Embeds 0
No embeds

No notes for slide

Pharmacogenomics

  1. 1. By,Shabnam RelhanM.Pharm(Biotech.) AIP
  2. 2. OVERVIEW Pharmacogenomics Single nucleotide polymorphism Importance of pharmacogenomics Examples of altered drug reponse Benefits of pharmacogenomics Pharmacogenomic drugs Ethical concerns Challenges to the growth and expansion
  3. 3. PHARMACOGENOMICS Pharmacology + Genomics = pharmacogenomics
  4. 4. PHARMACOGENOMICS IT IS THE BRANCH OF PHARMACOLOGY WHICH DEALS WITH THE INFLUENCE OF GENETIC VARIATION ON DRUG RESPONSE BY CO- RELATING GENE EXPRESSION OR SINGLE NUCLEOTIDE POLYMORPHISM WITH A DRUG’S EFFICACY OR TOXICITY. It is an approach to PERSONALIZED MEDICINE.
  5. 5. SINGLE NUCLEOTIDEPOLYMORPHISMS (SNPs) A Single Nucleotide Polymorphism (SNP) are DNA sequence variation that occurs when a single nucleotide in the genome sequence is altered. …CTAGATACGAACTGCATC… …CTAGATACGGACTGCATC… Occur in atleast 1% of the population and make up about 90% of all human genetic variation •Frequency: 1: 300 to 500 Nucleotides
  6. 6. Personalized Medicine It refers to an approach of clinical practice where a particular treatment is not chosen based on the ‘average pateint’ but on characteristic of an individual pateint.
  7. 7. Simple Definition
  8. 8. CorelationPharmacogenetics:- The study ofinherited differences or variations indrug metabolism and response.Pharmacogenomics:- The study of therole of inheritance in individualvariation in drug response.
  9. 9. IMPORTANCE OF PHARMACOGENOMICS “ONE SIZE FITS ALL” Only work for about60 percent of the population at the best. And the other 40 percent of the population increase their risks of adverse drug reaction because their genes do not do what is intended of them
  10. 10. ONE SIZE DOES NOT FIT ALL A 1998 study of hospitalized patients published in the Journal of the American Medical Association reported that in 1994, adverse drug reactions accounted for more than 2.2 million serious cases and over 100,000 deaths, making adverse drug reactions (ADRs) one of the leading causes of hospitalization and death in the United States.
  11. 11. EXAMPLES OF ALTERED DRUG RESPONSE ENZYME/DISEASES GENEGLUCOSE -6 -PHOSPHATE G6PDDEHYDROGENASE DEFICIENCYTHIOPURINE S-METHYL TRANSFERASE TPMTCYTOCHROME P450 ENJYME AND - CYP2D6DRUG METABOLISMWARFARIN AND COAGULATION CYP2C9 VKORC1
  12. 12. GLUCOSE 6-PHOSPHATE DEHYDROGENASE It is a cytosolic enzyme. Enjyme in Hexose Monophosphate Shunt It is a principal source of NADPH generation. NADPH is required to reduce the thiol groups on the glutathione and other proteins. Glutathione prevents the Red blood cells damage.
  13. 13. GLUCOSE 6- PHOHPHATEDEHYDROGENASE DEFICIENCY GSH deficiency in Red blood cells results in Membrane Fragility Haemolysis Hemolytic AnaemiaSYMPTOMS:- Prolonged neonatal jaundice Hemolytic Anaemia.
  14. 14. GLUCOSE 6- PHOHPHATEDEHYDROGENASE DEFICIENCY
  15. 15. SOME AGENTS THAT CAUSE HEMOLYSIS ING-6-P D DEFICIENT INDIVIDUALS Primaquine Nitrofurantoin Sulfacetamide Sulfanilamide Sulfapyridine
  16. 16. EXAMPLES OF ALTERED DRUG RESPONSE
  17. 17. Thiopurine methyl transferase It is an enjyme that methylates thiopurine compounds. The methyl donor is S- adenosyl-L- methionine which is converted to S-adenosyl-L-homocysteine. TPMT is best known for the role in the metabolism of thiopurine drugs such as :- Azathioprine 6- Mercaptopurine 6- thioguanine
  18. 18. THIOPURINE METHYLTRANSFERASE DEFICIENCY Decreased methylation Decreased inactivation of 6 MP Bone marrow toxicity Anaemia, Bleeding tendency, and infection.
  19. 19. EXAMPLES OF ALTERED DRUG RESPONSE
  20. 20. CYTOCHROME P450CYP:- It is a host of enzyme that use ironto oxidize things.Found in liver and small intestine.There are thousand different cytochromesAlthough the no. in man is only about 50
  21. 21. CYP ISOFORMSCYP3A4CYP2D6CYP2C9CYP2C19
  22. 22. CYTOCHROME P2D6 There is high expression of CYP2D6 in many persons of Ethiopian and Saudi Arabian origin. 2D6 is not inducible, so these people have developed a different strategy to cope with the high load of toxic alkaloids in their diet . These CYPs therefore chew up a variety of drugs, making them ineffective - many antidepressants and neuroleptics
  23. 23. CYTOCHROME P2D6 Deficiency Many individuals lack functional 2D6. These subjects will be predisposed to drug toxicity caused by antidepressants or neuroleptics Other drugs include: Dexfenfluramine Perhexiline (withdrawn from the market due to neuropathy)
  24. 24. EXAMPLES OF ALTERED DRUG RESPONSE
  25. 25. WARFARIN •The Most Commonly Prescribed Anticoagulant  •Patients Maybe: Resistant - Need Higher Dose to Prevent Strokes  Sensitive - Need Lower Dose to Prevent CNS Bleeds  • Warfarin Is Metabolised by the Cytochrome P450, Cyp2c9  • Warfarin Metabolism Involves Vitamin K Epoxide Reductase (VKORC1).
  26. 26. BENEFITS OFPHARMACOGENOMICS More Powerful Medicines Safer Drugs The First Time More Accurate Methods Of Determining The Dosages. Better Vaccines.
  27. 27. PHARMACOGENOMIC DRUGSHERCEPTINGLEEVAC
  28. 28. ETHICAL CONCERNS Many fear the implications pharmacogenomics can bring to their lives: 1. Through the development of individual pharmacogenomic profiles, an individuals privacy and confidentiality are at risk 2. Certain individuals (such as Health Insurance Companies or Employers) can obtain the profiles of others and use the "weak points" in their genes to discriminate (The U.S. Senate and the U.S. House of Representatives are attempting to pass the Genetic Information Nondiscrimination Act of 2007 in hopes of protecting individuals from genetic discrimination in terms of health insurance and employment).
  29. 29. ETHICAL CONCERNS 3. Since the drugs are more focused, the test groups become smaller, which can lead to rare and more fatal Adverse Drug Reactions 4. Developing drugs beneficial to one group but dangerous to another 5. Should physicians inform patients that due to their genetic makeup, they have a high chance of developing a disease that currently has no effective treatment?
  30. 30. ETHICAL CONCERNS 6. How will the FDA regulate the development and distribution of genetic tests and associated medicines? 7. It will become challenging to fully inform patients on possible risks. 8. Will these "personalized medicines" be available only to those who can afford it?
  31. 31. Challenges to the growth andExpansion Education of various healthcare providers regarding pharmacogenomics. Potentially smaller and more specialized drug markets. Resistance to genetic testing. Ethical & Legal issues. Expense.
  32. 32. REFERENCE One size does not fit all: The promise of pharmacogenomics A pharmacogenomics primer for the national centre for Biotecnology information(NCBI) Zdanowicz Martin M” Concept in Pharmacogenomics” page no-61-66 Ingelman-Sundberg et al. Polymorphic cytochrome P450 enzymes: an opportunity for individualized drug treatment Trends in Pharm Sci Aug 1999 342-9
  33. 33. Reference Eichelbaum M, Ingelman-Sundberg M, Evans WE. “Pharmcogenomics and individualized drug therapy”. Annu Rev Med. 2006.57:119-137. Dr D.P katare “Basics in Biotechnology”page no. 267- 269
  34. 34. THANK YOU

×